#Italy #Milan #Newronika #AlphaDBS #Keith Carlton

Newronika Strengthens Leadership with Keith Carlton's Appointment

Newronika, a renowned pioneer in the field of adaptive deep brain stimulation technology, has announced the appointment of Keith Carlton as its Executive Chairman. This significant move aligns with the company's ambition to enhance its strategic leadership during a crucial phase of global growth. With effective leadership experience in the medical device and neuromodulation sectors, Carlton is well-equipped to guide Newronika as it expands its operational footprint.

Leadership Background

Carlton brings a wealth of experience from his decades in the industry, where he has consistently driven both innovation and growth. This makes him an ideal figure to take the helm at Newronika, especially as the company embarks on the commercialization of its proprietary adaptive deep brain stimulation system, AlphaDBS. Lorenzo Rossi, Co-founder and CEO of Newronika, expressed enthusiasm about Carlton's appointment, emphasizing his strategic vision and proven track record in leading medical technology companies.

"We are honored to welcome Keith as our Executive Chairman," Rossi articulated, highlighting the pivotal role Carlton's leadership will play. Newronika's AlphaDBS is envisioned to offer advanced symptom relief for patients with Parkinson’s disease while minimizing any adverse side effects, showcasing the company's commitment to transformative healthcare solutions.

Future Direction and Priorities

In his new role, Mr. Carlton aims to leverage Newronika's innovative technology to redefine care standards for Parkinson's disease and other neurological disorders. He acknowledges the transformative potential that the company’s adaptive DBS technology possesses. Carlton stated, "The potential to redefine the standard of care for Parkinson’s disease is immense, and I look forward to working with the Board and our talented team to accelerate innovation and expand patient access."

A key priority for Carlton will be supporting the successful launch of the Phase III U.S. pivotal trial for AlphaDBS, showcasing the company's determination in bringing its groundbreaking solutions to the market. Moreover, this appointment comes on the heels of several of Newronika's recent accomplishments, such as securing CE Mark approval for AlphaDBS and receiving U.S. FDA IDE clearance.

Investments and Support

Newronika also recently finalized a significant funding round, securing €13.6 million through Series B financing, underscoring the investor confidence in the company’s strategic vision. Carlo Sanfilippo, a Senior Investment Manager at Indaco Venture Partners, reassured that Carlton's leadership expertise will guide the company through its next growth stages effectively.

About Newronika

Founded as a spin-off from the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, Newronika is at the forefront of advancing adaptive deep brain stimulation technology that optimizes therapy through real-time neurophysiological feedback. With its headquarters in Milan, Italy, Newronika is dedicated to furthering the field of neuromodulation with ongoing clinical initiatives in Europe, the U.S., and globally.

As Newronika embraces this new chapter with Keith Carlton at the helm, the industry can expect exciting developments in innovative treatment solutions that hold the promise of improving the quality of life for patients facing neurological challenges.

For more information, visit Newronika's website.